Canada’s Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a contribution of $62 million to support Entos Pharmaceuticals' $198.5 million project through the Strategic Innovation Fund.
This contribution will help build a 103,000-square-foot facility consisting of a biomanufacturing facility and research and development (R&D) centre. The facility will be used to produce genetic medicines with the potential to treat infections, cancer, rare diseases and neurodegenerative diseases. The company's leading innovative technology platform overcomes a key challenge related to delivering genetic medicines by targeting specific parts of the body where disease originates. This means that the company could potentially treat challenging conditions such as cystic fibrosis. The investment will also support increased domestic biomanufacturing capacity, build on Canadian strengths in an emerging technology area and ensure Canadians have access to novel medicines that address health emergencies such as pandemics.
With this contribution, Entos will be able to produce leading-edge therapeutics and vaccines in Edmonton, Alberta. The company will maintain and create 90 new good-paying jobs, and hire students for 69 co-op positions. The project will support the scale-up of this innovative Canadian biotechnology company and its platform, strengthen the supply chain for genetic medicines and significantly enhance Canada's ability to produce essential next-generation medicines for international markets.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!